Promissory Note
Note · Propanc Biopharma, Inc.
Reference: Promissory Note
- Original principal
- USD 82,500
- Outstanding
- —
- Commitment
- —
- Availability
- —
- Maturity
- Sep 15, 2025
Last reported interest terms: 10% Reported 2025-07-22 Later filings may not restate these terms; this does not confirm they still apply.
Covenant terms for this agreement are not yet verified.
Documents and filing history
-
Issuance
· 2025-07-18
Original principal USD 82,500 Exact source document
Parent 8-K filing · 2025-07-22
Effective July 18, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of 82,500 (the “Note”), for a purchase price of $75,000. The Company intends to use the net proceeds therefrom for general working capital purposes.
Issuer evidence: Effective July 18, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of 82,500 (the “Note”), for a purchase price of $75,000. The Company intends to use the net proceeds therefrom for general working capital purposes.
Supporting evidence: The maturity date of the Note is September 15, 2025 and bears interest at a rate of ten percent (10%) per annum. Repayment of the Note may occur as follows: (a) if the Company repays this Note on or before August 18, 2025, then Company shall pay Investor in cash the sum of one hundred percent (100%) of the sum of the outstanding principal amount of the Note (the “Principal Amount”) at such time, all accrued interest unpaid at such time, and any other payment due; and (b) if the Company repays the Note after August 18, 2025 and on or before September 18, 2025, then Company shall pay Investor in cash the sum of one hundred twenty percent (120%) of the sum of the outstanding Principal Amount at such time, all accrued interest unpaid at such time, and any other payment due (the “Maximum Repayment Amount”) or (b) at such time as the Company and the Investor may agree to effect repayment.
Supporting evidence: Effective July 18, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of 82,500 (the “Note”), for a purchase price of $75,000. The Company intends to use the net proceeds therefrom for general working capital purposes.